Cancer treatment and research communications最新文献

{"title":"Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting","authors":"Firas Badin","doi":"10.1016/j.ctarc.2024.100803","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100803","url":null,"abstract":"<div><p>Small cell lung cancer (SCLC) is characterized by high initial responses to platinum-based chemotherapy plus immune checkpoint inhibitors; however, most patients quickly relapse and require subsequent treatment. Second-line treatment options in SCLC remain limited, and treatment algorithms are not completely consistent across the available guidelines in this setting. This review highlights key considerations regarding selection of second-line treatment for patients with relapsed SCLC. In particular, the role of lurbinectedin, which was first approved in 2020, representing the first significant addition to treatment algorithms in this setting for decades, is summarized. Future directions, including the identification of SCLC subtypes and the need for predictive biomarkers to guide patient selection and targeted therapy, are also discussed.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"39 ","pages":"Article 100803"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000157/pdfft?md5=b29452b22f58508bfc26f6b0891ea943&pid=1-s2.0-S2468294224000157-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140122964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoexpression pattern of TLR3 and TLR7 in minor salivary gland adenoid cystic carcinoma and its role in prognosis","authors":"Aleksi Rytkönen ,&nbsp;Mine Eray ,&nbsp;Auli Suominen ,&nbsp;Antti Mäkitie ,&nbsp;Caj Haglund ,&nbsp;Jaana Hagström ,&nbsp;Hanna K. Laine","doi":"10.1016/j.ctarc.2024.100822","DOIUrl":"10.1016/j.ctarc.2024.100822","url":null,"abstract":"<div><h3>Objectives</h3><p>Adenoid cystic carcinoma (ACC) of the salivary glands has poor long-term prognosis and a high metastatic rate. Toll-like receptors (TLRs), first-line immune activators, have been associated with both tumor progression and suppression. We aimed to study TLR3 and TLR7 behavior in ACC.</p></div><div><h3>Materials and methods</h3><p>We studied TLR3 and TLR7 immunoexpression of 46 minor salivary gland ACCs diagnosed at the Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland over the period 1974–2012. The associations of TLR3 and TLR7 immunoexpression with clinicopathological factors were evaluated by χ²-test and Fisher's exact test.</p></div><div><h3>Results</h3><p>In the majority of samples, both TLR3 and TLR7 were immunoexpressed in cytoplasm. The immunoexpression was heterogeneous between individual tumors. Stronger TLR7 immunoexpression associated with recurrence rate and poorer disease-specific survival (DSS). TLR3 did not associate significantly with survival although we found an inverse correlation between TLR3 and TLR7 immunopositivity. Hence, when TLR3 immunoexpression was negative or mild, TLR7 immunoexpression was moderate to strong, and vice versa.</p></div><div><h3>Conclusions</h3><p>TLR3 and TLR7 are immunoexpressed in minor salivary gland ACC. TLR7 is potentially an independent prognostic marker for recurrence rate and DSS.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100822"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000340/pdfft?md5=8bb1c84fbf9eeb9995a07d3feeb8cf80&pid=1-s2.0-S2468294224000340-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141137449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with delay in diagnosis of oral cancers","authors":"Deepa Swaminathan,&nbsp;Nebu Abraham George,&nbsp;Shaji Thomas,&nbsp;Elizabeth Mathew Iype","doi":"10.1016/j.ctarc.2024.100831","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100831","url":null,"abstract":"<div><h3>Background</h3><p>Oral cancer is one of the ten most common malignancies in the world and approximately 90 % of cases are OSCC. Despite the progress in available treatment modalities, the mortality of patients with OSCC has remained steadily high during the last 20 years. Survival data is strongly influenced by the timing of diagnosis: with more than 50 % of patients being diagnosed at an advanced stage, and their 5-year survival rate being less than 50 %. Therefore, early diagnosis plays a crucial role in improving a patient's prognosis, as early stage cancers show a survival rate of over 90 %, whereas it drops to 5–20 % stage III and IV disease. This prospective study has been conducted with an aim of assessing diagnostic delays and looking at the various patient and tumour factors and their association with them.</p></div><div><h3>Methodology</h3><p>This prospective observational study was conducted from December 2023 to February 2024. The cases for the present study included cases of oral squamous cell carcinoma diagnosed by clinical, radiological and/or histological confirmation. The patient delay was recorded in days as informed by the patients themselves, about the onset of their symptoms to time taken to seek medical attention. This was then associated with various patient and tumour related factors.</p></div><div><h3>Result</h3><p>A total of 120 (n) patients were interviewed and these patient's case sheets were recruited for the present study. The median primary delay for the entire population was found to be 90 days while the median secondary delay was 11 days. The median total delay was found to be 106 days. The median total delay was higher among females and younger population though this was not statistically significant. However education showed a significant impact with literate patients presenting much earlier. Smoking and alcohol abuse did not show a significant effect on delay. Various tumour factors also did not show any statistically significant effect on delay although, patients with advanced stage and nodal secondaries presented at a much later time.</p></div><div><h3>Conclusion</h3><p>Both patient and tumour related factors as well as the decisions made during the first contact with health care providers influence delay before specialist consultation. Raising awareness of HNC symptoms among the general population and GPs is the way to get patients to curative treatment without long delay.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100831"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000431/pdfft?md5=9c724da23d2ea1767e062dbbb664435b&pid=1-s2.0-S2468294224000431-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141594247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional status, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio as prognostic factors of one-year survival rate in elderly patients with advanced-stage non-small cell lung cancer","authors":"Ratna Nurhayati ,&nbsp;Aulia Rizka ,&nbsp;Cleopas Martin Rumende ,&nbsp;Noorwati Sutandyo ,&nbsp;Arif Hanafi ,&nbsp;Edy Rizal Wahyudi ,&nbsp;Hamzah Shatri ,&nbsp;Anna Mira Lubis ,&nbsp;Em Yunir ,&nbsp;Muhammad Firdaus ,&nbsp;Yuniar Harris Prayitno ,&nbsp;Nadira Nibras Taqiyya","doi":"10.1016/j.ctarc.2024.100859","DOIUrl":"10.1016/j.ctarc.2024.100859","url":null,"abstract":"<div><h3>Background and aim</h3><div>Non-small cell lung cancer (NSCLC) is the most common lung cancer found in elderly patients. Aging and chronic inflammation are related to its pathogenesis. Functional status, lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio describe a chronic inflammation and correlate to the survival of older adults with advanced-stage (IIIB-IV) NSCLC. This study aims to determine functional status, lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio as prognostic factors to 1-year survival in elderly patients with NSCLC stage IIIB-IV.</div></div><div><h3>Methods</h3><div>Survival analysis with a cohort retrospective study is conducted on elderly patients with NSCLC stage IIIB-IV in Dharmais National Cancer Center Hospital between January 2020 and June 2022. Medical records were collected, comprising complete blood count prior to chemotherapy or radiotherapy, assessment of functional status through the Barthel Index for Activities of Daily Living (ADL), and 1-year survival post-diagnosis. Factors potentially influencing outcomes included diabetes mellitus, anemia, chronic obstructive pulmonary disease, and chronic kidney disease. Statistical analyses were performed using SPSS 20.0, employing the log-rank method for bivariate analysis and Cox regression for multivariate analysis.</div></div><div><h3>Results</h3><div>In a cohort of 108 patients, the majority were aged 60–69 years (74.1 %), male (66.7 %), diagnosed at stage IV (80.5 %), and with adenocarcinoma subtype (75.0 %). Significant correlations were observed between the lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio with the 1-year survival rate in elderly patients with stage IIIB-IV NSCLC (<em>p</em> = 0.015 and <em>p</em> = 0.001, respectively). Functional status did not show a significant correlation with 1-year survival overall (<em>p</em> = 0.540), but significant correlations were noted in patients receiving chemotherapy (<em>p</em> = 0.044) and radiotherapy (<em>p</em> = 0.009).</div></div><div><h3>Conclusion</h3><div>The lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio provide significant prognostic insights regarding 1-year survival in elderly patients diagnosed with stage IIIB-IV non-small cell lung cancer (NSCLC). In contrast, the functional status of these patients does not demonstrate a significant correlation with one-year survival.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100859"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of digital breast tomosynthesis (DBT) versus digital mammography (DM) in a population clinically referred for breast imaging – a retrospective cohort study","authors":"Naomi Noguchi ,&nbsp;Farzaneh Boroumand ,&nbsp;Katy Bell ,&nbsp;Margaret Pooley ,&nbsp;Aileen Zeng ,&nbsp;Lauren Arnold ,&nbsp;Armando Teixeira-Pinto ,&nbsp;Nehmat Houssami","doi":"10.1016/j.ctarc.2025.100865","DOIUrl":"10.1016/j.ctarc.2025.100865","url":null,"abstract":"<div><h3>Purpose</h3><div>To compare the performance of Digital Breast Tomosynthesis (DBT) with Digital Mammography (DM) in patients clinically referred for breast imaging.</div></div><div><h3>Methods</h3><div>Diagnostic performance of DBT (in 2016, after transition to DBT) was compared with DM (in 2011, before the transition) in consecutively referred patients (N = 10,742 exams). Reference standard was outcomes from all tests including histopathology and clinical review within the same year. Primary outcome was area under receiver operating characteristic curve (AUC-ROC).</div></div><div><h3>Results</h3><div>Cancer rates did not differ between DBT (1.72 % (CI 1.38–2.15 %)) and DM (1.71 % (CI 1.40–2.08 %)). AUC-ROC was similar for DBT (0.91 (CI 0.87–0.95)) and DM (CI 0.91 (0.88–0.95)). Abnormal interpretation rate for DBT was 2.83 % (CI 2.38–3.36 %) and for DM it was 2.17 % (CI 1.82–2.58 %), and the biopsy rate for DBT was 8.2 % (CI 7.4–9.0 %) and for DM it was 9.9 % (CI 9.1–10.6 %)).</div><div>In patients with dense breasts (vs overall cohort) AUC-ROC and sensitivity were lower for both DM and DBT. Within this subgroup, AUC-ROC for DBT was 0.90 (CI 0.84–0.95) and for DM it was 0.85 (CI 0.79–0.92), sensitivity was 78.2 % (CI 65.0–88.2 %) for DBT and 64.8 % (CI 50.6–77.3 %) for DM, and ultrasound was accurate whether it was used with DBT (AUC-ROC 0.95 (CI 0.91 – 0.99)) or DM (AUC-ROC 0.95 (CI 0.90 – 0.99))</div></div><div><h3>Conclusion</h3><div>In clinically referred patients, diagnostic accuracy and diagnostic yield were similar between DBT and DM. DBT may have a higher abnormal interpretation rate but a lower biopsy rate. DBT may be more accurate than DM in dense breasts.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100865"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143073985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials","authors":"Samuel Pratama ,&nbsp;Lowilius Wiyono ,&nbsp;Martien Silviandy Setiawan ,&nbsp;Brigitta Cindy Lauren","doi":"10.1016/j.ctarc.2025.100874","DOIUrl":"10.1016/j.ctarc.2025.100874","url":null,"abstract":"<div><h3>Background</h3><div>Small Cell Lung Cancer (SCLC) is a neuroendocrine carcinoma characterized by aggressive behavior and poor prognosis with limited treatment options. Poly ADP-Ribose Polymerase inhibitors (PARPi) are novel anti-cancer agents that induce DNA damages and cause cell death in tumor cells with impaired DNA repair, known as the synthetic lethality concept. This study aimed to analyze the efficacy and safety of PARPi for patients with SCLC from available clinical trial data.</div></div><div><h3>Methods</h3><div>Studies reporting efficacy and safety of PARPi therapy for SCLC patients were searched across five databases with predetermined eligibility criteria in accordance with the PRISMA statement. Critical appraisal was done using suitable tools, outcomes were extracted, and analyzed.</div></div><div><h3>Results</h3><div>Five randomized controlled clinical trials with 451 interventional patients and 308 control patients with SCLC were included. The analysis showed increased Progression-Free Survival (PFS) (RR 0.92 (95 %CI 0.84–1.00; p=0.05)) and Objective Response Rate (ORR) (RR 1.27 (95 %CI 1.07–1.50; p=0.007)), no significant difference in Overall Survival (OS) (RR 1.03 (95 %CI 0.92–1.15; p=0.60)), and an increased risk for serious Treatment Emergent Adverse Events (TEAEs) (RR 1.13 (95 %CI 0.95–1.35; p=0.16)) in PARPi-receiving SCLC patients. Amongst the hematologic toxicities, sub-analysis showed that thrombocytopenia had the highest risk, followed by neutropenia, anemia, leukopenia, and lymphopenia.</div></div><div><h3>Conclusion</h3><div>The addition of PARPi in the chemotherapy regimen for patients with SCLC results in increased PFS and ORR, with no difference in OS and an increased risk of TEAEs. Further and larger clinical studies are needed to validate the efficacy and safety of PARPi therapy for SCLC patients.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100874"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143073986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"En plaque meningioma of the temporal bone: A systematic review on the imaging and management of a rare tumor","authors":"Arianna Burato ,&nbsp;Giuseppe Maruccio ,&nbsp;Livio Presutti ,&nbsp;Ignacio Javier Fernandez ,&nbsp;Gabriele Molteni ,&nbsp;Giulia Molinari","doi":"10.1016/j.ctarc.2024.100854","DOIUrl":"10.1016/j.ctarc.2024.100854","url":null,"abstract":"<div><h3>Objective</h3><div>To review the published cases of meningioma en plaque of the temporal bone (TB-MEP), to gather evidence on the clinical assessment and management of this rare entity.</div></div><div><h3>Methods</h3><div>Following PRISMA statement recommendations, 383 abstracts were screened independently by two authors. Inclusion criteria were articles of human patients affected by TB-MEP; English or Italian language; availability of the abstract articles unrelated to TB-MEP, guidelines and systematic reviews were excluded. Only full-text articles reporting the diagnostic work-up and the management of the TB-MEP were considered for analysis.</div></div><div><h3>Results</h3><div>A total of 12 articles were included, for a total of 25 patients with a mean age of 52 years (range: 31–71). The average time elapsed between the onset of symptoms and the actual diagnosis of TB-MEP was 36.5 months (range: 2–120). In most cases, the pathology presented with hearing loss (80 %), often accompanied by effusive otitis media (52 %), aural fullness (32 %), and tinnitus (32 %). The main Computed Tomography (CT) findings were hyperostosis (76 %), hairy appearance of bony margins (16 %), involvement of the mastoid and middle ear (48 %). Magnetic Resonance Imaging (MRI) revealed dural enhancement (28 %), temporal hyperostosis (20 %), a clearly enhancing extra-axial mass (28 %), compression of the surrounding vasculo-nervous structures (8 %) and the possible involvement of the temporal lobe (8 %). Forty percent of patients underwent various medical and surgical treatment before reaching the diagnosis. Forty-four percent of patients were sent to definitive surgical treatment, 44 % to follow-up while 8 % received radiotherapy.</div></div><div><h3>Conclusions</h3><div>Meningioma en plaque (MEP) is a rare tumour, particularly when it originates within the temporal bone. Appropriate imaging in patients complaining of audiological sign and symptoms is mandatory to avoid diagnostic delays, avoid inappropriate surgical procedures, and adopt the appropriate treatment.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100854"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review of the efficacy and safety of iodine-125 seed implantation for lung cancer treatment","authors":"Zhouzhou Li ,&nbsp;Zhigang Hu ,&nbsp;Xiaoqi Xiong ,&nbsp;Xinyu Song","doi":"10.1016/j.ctarc.2024.100844","DOIUrl":"10.1016/j.ctarc.2024.100844","url":null,"abstract":"<div><div>Lung cancer is the second most common, and the deadliest, disease globally. Because it is often diagnosed late, surgical resection is not a viable treatment option for ∼75 % of patients, often resulting in a poor prognosis. Of the available treatments, radioactive iodine-125 (125-I) seed implantation therapy, or brachytherapy, has emerged as a promising option. In this procedure, small radioactive seeds are implanted inside tumor cells to produce sustained effects. Because of the short radial distance of this radiation, 125-I brachytherapy selectively and efficiently kills cancer cells while minimizing injury to adjacent cells. The present review describes the mechanism of 125-I seed implantation in the treatment of lung cancer, its efficacy and safety, and its combination with other therapies. We conclude that radioactive 125-I seed implantation and its use in combination with other therapies are good options for the management of local tumor growth, pain palliation, and improving the life span of patients suffering from lung cancers. This technique can enhance the clinical efficacy of treatment and improve the overall survival of patients with lung cancers. However, standardized dosage regimens and other procedures are still required to achieve treatment homogeneity and provide guidance for the clinical implementation of this technique.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"41 ","pages":"Article 100844"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant treatment for pancreatic cancer: Controversies and advances","authors":"Douglas Dias e Silva,&nbsp;Vincent Chung","doi":"10.1016/j.ctarc.2024.100804","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100804","url":null,"abstract":"<div><p>Despite the advancements in the treatment of localized pancreatic cancer, several unresolved issues persist in clinical practice, especially in the neoadjuvant setting. These include determining the criteria for selecting patients for treatment, identifying the most effective chemotherapy regimens, understanding the role of radiotherapy, and accurately assessing how patients respond to treatment. Current strategies for assessing patients before surgery involve thoroughly evaluating their overall health status, analyzing tumor markers, and using advanced imaging techniques. However, existing methods for staging the disease still have limitations when it comes to accurately detecting metastatic cancer. The ongoing debate between performing surgery upfront or administering neoadjuvant therapy highlights the need for robust clinical evidence to guide treatment decisions effectively. This review analyzes the evidence regarding controversial topics in neoadjuvant pancreatic cancer treatment and discusses further research efforts to enhance patient outcomes. To improve the outcomes found with surgery alone, multimodal treatment with chemotherapy.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"39 ","pages":"Article 100804"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000169/pdfft?md5=6d8a6f727efbbfd3a66c92d8f73f2c89&pid=1-s2.0-S2468294224000169-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140163393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implant reconstruction after mastectomy–A review and summary of current literature","authors":"Thomas Kidd,&nbsp;Gerard Mccabe,&nbsp;Joanna Tait,&nbsp;Dhananjay Kulkarni","doi":"10.1016/j.ctarc.2024.100821","DOIUrl":"10.1016/j.ctarc.2024.100821","url":null,"abstract":"<div><h3>Introduction</h3><p>The landscape of breast reconstruction has changed significantly with a shift in focus to include the restoration of a patient's quality of life after cancer. Reconstructive options can be divided into alloplastic (implant based) and autologous (tissue based). This paper aims to provide a current educational summary regarding implant-based reconstruction after breast cancer surgery and review the current literature.</p></div><div><h3>Method</h3><p>A review of the literature was conducted utilising standard PRISMA flowchart. Databases searched included Pubmed, EMBASE, and MEDLINE.</p></div><div><h3>Results</h3><p>Current practice is explored within the text, including types of implants, indications, and surgical approaches. Heterogenous cohorts, surgical technique variation, and selection bias can make comparison of the literature challenging. The major evidence reviews of implant-based reconstruction topics are discussed including, ADM use, radiotherapy, and complications. Despite the benefits of autologous reconstruction, implant-based techniques still represent a significant proportion of reconstructive breast procedures. However, implant-reconstruction is not without its risks and limitations and, with such variety in practice, there remains a lack of high-quality evidence guiding practice. Most importantly, patients need to be counselled about the pros and cons of each choice, particularly with the increasing utilisation of radiotherapy post-reconstruction. Ultimately, the patient and surgeon should reach a decision in full knowledge of the risks and potential outcomes.</p></div><div><h3>Conclusions</h3><p>Further research is required into implant-based reconstructive therapy, which will allow a greater consensus for management and a pathway for both surgeons and patients.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100821"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000339/pdfft?md5=ff6ed00651ee34dc6bcace7f6346b888&pid=1-s2.0-S2468294224000339-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141142766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}